Quarterly report · Q3
3151.TEDINET S100SUKH
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥448.9bn | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥581.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥444.4bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥5.7bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥3.1bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥6.5bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.3bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥7.6bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥4.1bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.1bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.1bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥2.5bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥328.3bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥297.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥336.1bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥225.6bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥197.2bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥102.7bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥100.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥102.4bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥31.1bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥19.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥99.12 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.66 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.69 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.59 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.22 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.1% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-12-31 | ¥4.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-12-31 | ¥2.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-12-31 | −¥162m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥10.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥10.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | ¥61m |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥431.3bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥423.2bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥5.2bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥14.3bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥14.3bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥9m |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥259m |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥8.5bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥8.5bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥0 |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥288m |
| —segment total | revenue | 2023-04-01 → 2023-12-31 | ¥454.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-12-31 | ¥446.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥8.0bn |
| —segment total | segment profit | 2023-04-01 → 2023-12-31 | ¥5.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥458.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥448.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥5.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥4.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | −¥236m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥9.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥9.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥126m |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥427.4bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥419.4bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| jpcrp040300-q3r_E22440-000Medical Products Wholesalereportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥13.8bn |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| jpcrp040300-q3r_E22440-000Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥77m |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥8.2bn |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E22440-000Veterinary Drugs Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥283m |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥449.4bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥441.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥8.0bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥3.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥454.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥444.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥9.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥2.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 377
| Item | Context | Value | Unit |
|---|---|---|---|
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 999900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0193 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 999900 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 999900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0193 | |
| Cash and deposits | Prior1YearInstant | 19029000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 31100000000 | JPY |
| Notes and accounts receivable trade | Prior1YearInstant | 118585000000 | JPY |
| Notes and accounts receivable trade | CurrentQuarterInstant | 131235000000 | JPY |
| Inventories | Prior1YearInstant | 30846000000 | JPY |
| Inventories | CurrentQuarterInstant | 33863000000 | JPY |
| Accounts receivable other | Prior1YearInstant | 16466000000 | JPY |
| Accounts receivable other | CurrentQuarterInstant | 16523000000 | JPY |
| Other ca | Prior1YearInstant | 3616000000 | JPY |
| Other ca | CurrentQuarterInstant | 2903000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -41000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -50000000 | JPY |
| Current assets | Prior1YearInstant | 188502000000 | JPY |
| Current assets | CurrentQuarterInstant | 215575000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 20370000000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 19601000000 | JPY |
| Land | Prior1YearInstant | 24917000000 | JPY |
| Land | CurrentQuarterInstant | 25083000000 | JPY |
| Other net ppe | Prior1YearInstant | 3736000000 | JPY |
| Other net ppe | CurrentQuarterInstant | 4062000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 49024000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 48747000000 | JPY |
| Goodwill | Prior1YearInstant | 818000000 | JPY |
| Goodwill | CurrentQuarterInstant | 716000000 | JPY |
| Other ia | Prior1YearInstant | 2558000000 | JPY |
| Other ia | CurrentQuarterInstant | 3339000000 | JPY |
| Intangible assets | Prior1YearInstant | 3377000000 | JPY |
| Intangible assets | CurrentQuarterInstant | 4055000000 | JPY |
| Investment securities | Prior1YearInstant | 44642000000 | JPY |
| Investment securities | CurrentQuarterInstant | 47563000000 | JPY |
| Other ioa | Prior1YearInstant | 12771000000 | JPY |
| Other ioa | CurrentQuarterInstant | 13159000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -1002000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -756000000 | JPY |
| Investments and other assets | Prior1YearInstant | 56411000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 59966000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 108813000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 112769000000 | JPY |
| Assets | Prior1YearInstant | 297316000000 | JPY |
| Assets | CurrentQuarterInstant | 328344000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 164571000000 | JPY |
| Notes and accounts payable trade | CurrentQuarterInstant | 195107000000 | JPY |
| Short term loans payable | Prior1YearInstant | 990000000 | JPY |
| Short term loans payable | CurrentQuarterInstant | 980000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |